

## Guidelines for reporting data to the EBMT Activity Survey 2011.

**Table 1: Report the total number of patients receiving their 1st transplant in your centre in 2011. Report the first allogeneic transplant and/or first autologous transplant per patient according to disease indication, donor type and stem cell source as outlined in Table 1. You may include the same patient twice as long as the first occurrence of each type of transplant took place in 2011.**

The following EBMT/JACIE/FACT definitions for '**first transplants**' apply:

- first transplant (new patient, never transplanted before)
- first allograft (after a previous autograft) or first autograft (after a previous allograft)
- first allograft or first autograft in your centre after a previous transplant in a different centre.

The column '**total allo after auto**' refers to patients with their disease treatment in a planned 'allo after auto' transplant programme. Enter these patients in both the respective allogeneic or autologous transplant section in the main table **and if applicable** in the column '*total allo after auto*' on the right side.

The following definitions for donor type and stem cell source apply:

- Non-id = any family member (matched or mismatched) other than HLA-identical sibling or twin.

For combinations of stem cell products / donor types please report as follows:

- Bone marrow and peripheral blood = peripheral blood stem cell transplant - enter as PBSC
- Bone marrow and cord blood = cord blood transplant - enter as Cord
- Peripheral blood and cord blood = cord blood transplant - enter as Cord
- Bone marrow and peripheral blood + cord blood = cord blood transplant - enter as Cord
- Autologous stem cells given together with an allogeneic transplant within 7 days = allogeneic transplant
- Multiple infusions of the same product, e.g. double cord, multiple cord, multiple PBSC, within one week are reported as **one transplant only**.

**Table 2: Report the total number of retransplants and additional (non-first) transplants performed by donor type and stem cell source in 2011.**

The following definitions for Table 2 apply only if the rules for 1st transplants do not apply:

- A **Retransplant** is an unplanned transplant performed due to relapse or progression of the disease, rejection of the first transplant or for any other new indication.
- An **Additional transplant** (non-first transplant) is when a double, triple or more 'multiple graft programme' is planned from the beginning of the treatment protocol. Report only those that were given in the survey year.
- **Re-infusion of allogeneic stem cells** for graft failure is considered to be a retransplant. Enter in **Table 2** as a retransplant.
- **Re-infusion of autologous stem cells** for non-engraftment is considered to be a boost and is **not a transplant**.

The total number of ALL TRANSPLANTS (bottom row of Table 2) performed in 2011 is calculated as the total number of transplants from Table 1 + the transplants entered in Table 2.

**Table 3: collects generic information for patients (i.e. total numbers only) given cellular therapies or other technologies.**

**\*\*If you have data to report here, please also report it on the more detailed survey on cellular therapies.**

- **Hematopoietic Stem Cells (HSC) for non-hematopoietic use:** enter the number of patients receiving HSC transplants for NON-hematopoietic use in 2011.
- **\*MSC (Mesenchymal stromal cells):** enter the total number of patients receiving MSC stromal cell infusions in 2011 by donor type. The donor type refers to the MSC cells itself: eg: If patient received an allogeneic transplant and auto MSC, enter the MSC as 'auto'. Include MSC therapy given for transplant related reasons (GvHD prevention or treatment, graft enhancement or bone marrow failure) or for any other indication (please specify in table).
- **Non Myeloablative transplants** (previously called Reduced Intensity Conditioning transplants): enter the total number of all non myeloablative transplants performed in 2011 (this includes first HSCT from Table 1 and/or re- or additional HSCT from Table 2). The definition of these transplants can be viewed on the EBMT website under the 'Registry - Transplant Activity survey' link.
- **DLI (Donor Lymphocyte Infusions):** enter the total number of patients receiving DLI in 2011. The year the transplant was done does not affect the DLI reporting itself.

**Disease classification dictionary:** the classification of diseases for the survey follows the EBMT disease classification dictionary, which can be found at: [www.ebmt.org](http://www.ebmt.org) - Registry - Transplant Activity survey – Alphabetical list of Disease Classifications.

Do not hesitate to contact me if you have any questions; telephone on +41 61 265 3203

**Please note that reporting to the activity survey does not substitute for sending the MED-AB data to the EBMT registry.**

**Please send the completed EBMT Activity Survey by post to:**

**Helen Baldomero, Hematology, University Hospital Basel, Petersgraben 4, CH 4031, Basel, Switzerland or by E mail: [baldomero@uhbs.ch](mailto:baldomero@uhbs.ch). FAX: + 41 61 265 2735.**